Author Details :
Volume : 4, Issue : 3, Year : 2018
Article Page : 226-231
https://doi.org/10.18231/2581-4729.2018.0048
Abstract
Introduction: Warts are benign epidermal proliferations of skin and mucosa caused by human papilloma virus. Destructive therapeutic modalities are limited by cost, pain, scarring. Immunotherapy is a new modality which acts on enhancing cell mediated immunity.
Objective: This study aims to evaluate and compare efficacy of intralesional vitamin D3 and purified protein derivative (PPD) in treatment of warts.
Materials and Methods: It is a prospective hospital based comparative study among 40 patients with warts. Patients were randomly and equally divided. Group A patients were given intralesional vitamin D3 (0.2ml of 15mg/ml into each wart) and Group B patients were given intralesional PPD (0.2ml of 5TU/ml into each wart). The injections were repeated every 2 weeks until complete clearance. Decrease in size and number of lesions were evaluated and photographic record was maintained. Patients were followed up after 3 months. Unpaired t test was used for statistical analysis.
Results: The study found that 14 out of 20 patients (70%) of Group A showed complete response after 4 sessions and 6 patients (30%) showed moderate response. 17 out of 20 patients (85%) of Group B showed complete response, 2 patients (10%) showed moderate response, 1 patient (5%) showed no response. Recurrence was observed in 1 patient after 3 months who received vitamin D3. No serious adverse effects were observed.
Conclusion: Both vitamin D3 and PPD showed positive results with PPD having faster and better efficacy in treatment of multiple common warts.
Keywords: Immunotherapy, Warts, Intralesional, Vitamin D3, Tuberculin purified protein derivative.
How to cite : Akula M L, Shetty M, Shetty V, Patel P, Basil A, Comparative study of therapeutic efficacy of intralesional vitamin D3 versus intralesional purified protein derivative in the treatment of warts. IP Indian J Clin Exp Dermatol 2018;4(3):226-231
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Viewed: 1727
PDF Downloaded: 894